Preferred Label : selumetinib;
UMLS semantic type : T109 - Organic Chemical; T121 - Pharmacologic Substance;
Is substance : O;
Origin ID : M0557447;
UMLS CUI : C2980074;
ATC code(s)
Currated CISMeF NLP mapping
Related record
Semantic type(s)
UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3322781/fr/koselugo-selumetinib
2022
false
false
false
France
selumetinib
treatment outcome
insurance, health, reimbursement
Mitogen-Activated Protein Kinase Kinase Inhibitor
MAPK-ERK kinases
child
Neurofibromatosis Type 1 with Inoperable, Progressive, Symptomatic Plexiform Neurofibromas
neurofibroma, plexiform
neurofibromatosis 1
protein kinase inhibitors
protein kinase inhibitors
administration, oral
selumetinib
evaluation of the transparency committee
selumetinib
---
https://www.cadth.ca/fr/selumetinib
2022
false
false
false
Canada
French
English
drug evaluation
canada
selumetinib
neurofibromatosis 1
child
---
https://ansm.sante.fr/tableau-atu-rtu/selumetinib-10-mg-gelules
2021
false
false
false
France
French
administration, oral
selumetinib
selumetinib
summary of product characteristics
package leaflet
guidelines for drug use
child
neurofibromatosis 1
neurofibroma, plexiform
Mitogen-Activated Protein Kinase Kinase Inhibitor
MAPK-ERK kinases
protein kinase inhibitors
Product containing precisely selumetinib 25 milligram/1 each conventional release
oral capsule (clinical drug)
Product containing precisely selumetinib 10 milligram/1 each conventional release
oral capsule (clinical drug)
Tyrosine Kinase Inhibitors
AZD 6244
Mitogen-Activated protein kinase kinases
benzimidazoles
---
https://www.ema.europa.eu/en/medicines/human/EPAR/koselugo
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
selumetinib
selumetinib
orphan drug production
neurofibroma, plexiform
neurofibromatosis 1
child
administration, oral
MAP kinase kinase 1
MAP kinase kinase 2
selumetinib
product surveillance, postmarketing
drug interactions
drug evaluation, preclinical
Product containing only selumetinib in oral dose form (medicinal product form)
Neurofibromatosis Type 1 with Inoperable, Progressive, Symptomatic Plexiform Neurofibromas
Tyrosine Kinase Inhibitors
---